Central Alabama Veterans Health Care System-West Campus, Montgomery, AL
Is Central Alabama Veterans Health Care System-West Campus registered with the FDA as a 503B outsourcing facility?
No matching record found in FDA’s registered outsourcing facility list (updated Nov 6, 2026) on Nov 15, 2026, searching by name and location. FDA’s compounding inspections and actions page labels it a 503A facility.
Does Central Alabama Veterans Health Care System-West Campus hold a Alabama pharmacy license?
State board of pharmacy records for Alabama are not checked: the Board of Pharmacy sends its license roster only by email, after the requester agrees to terms that limit how the data may be used, and its license verification is an interactive search.
Has Central Alabama Veterans Health Care System-West Campus had a state board action or FDA letter?
FDA letters: no matching record found on FDA’s compounding inspections and actions page (current as of Oct 22, 2026, covering 2019 on) on Nov 15, 2026; the page lists 1 Form 483 (Apr 16, 2026) for Central Alabama Veterans Health Care System-West Campus. State board of pharmacy records for Alabama are not checked: the Board of Pharmacy sends its license roster only by email, after the requester agrees to terms that limit how the data may be used, and its license verification is an interactive search.
FDA registers 503B outsourcing facilities; state boards of pharmacy license pharmacies, including 503A compounding pharmacies, and keep their own disciplinary records. Neither FDA list says which drugs a pharmacy makes.
- Names in FDA records
- Central Alabama Veterans Health Care System-West Campus
- Location
- Montgomery, AL
- Type as FDA labels it
- 503A
- FDA 503B list
- No matching record found
- Form 483s on FDA’s actions page
- 1
- Warning letters on FDA’s actions page
- 0
- Latest action on that page
- Apr 16, 2026
- FDA Data Dashboard inspections
- No matching site found
- Form 483 text on this page
- 1 Form 483, 8 observations
- State board records
- Not checked
FDA inspections and letters
FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists this pharmacy as Central Alabama Veterans Health Care System-West Campus, a 503A facility, with 1 dated action.
| Document | |||
|---|---|---|---|
| Apr 16, 2026 | Form 483 | 483 Issued 04/16/2026 | fda.gov |
A Form 483 lists investigator observations, not a final FDA determination.
FDA inspection classifications and published Form 483s
No inspected site under this exact name and city was found in the FDA Data Dashboard on Nov 15, 2026, searching 12,593 US sites with a drug inspection ending Oct 1, 2008 to Oct 23, 2026. FDA may list the site under another legal name, so this is not a finding that it was never inspected.
Form 483 observations
A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.
FDA’s published Form 483 for this site has 8 numbered observations in all. Each observation is quoted from the PDF as FDA numbered it, with long ones cut and linked to the full form. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.
Inspection Apr 8, 2026 to Apr 16, 2026: 8 observations
- Firm on the cover
- Central Alabama Veterans Health Care System -West Campus, 215 Perry Hill Rd, Montgomery, AL 36109-3725
- FEI number
- 1073935
- Establishment type on the cover
- producer of sterile drug products
- FDA district office on the cover
- 404 BNA Dr., Bldg. 200, Ste. 500 Nashville, TN 37217-2597
- Matched to this page by
- firm name, city and state on the cover; linked from actions page
- FDA document
- Read the full 483 (PDF on fda.gov)
Observation 1
Failure to conduct media fills that closely simulate aseptic production operations under the worst-case, most-challenging, and stressful conditions.
Specifically,
A. The media fill instructions in section S(k) of SOP 119-19-12 require compounders use <Redacted B4> Validation <Redacted B4> which contains <Redacted B4>, and <Redacted B4>. The <Redacted B4> during media fill does not closely simulate the <Redacted B4> consecutive drug product vials I saw <Redacted B4> during routine compounding of Remicade (inflixiniab) 750 mg Sodium Chloride 0.9% 250 mL compound sterile product (CSP), barcode 719803357553V28, Oil 04/10/26.
I
B. Compounders use a new syringe for every vial and ampule during media fill. I watched a compunder using the same syimge to <Redacted B4> <Redacted B4> vials during routine compounding of Remicade (infliximab) 750 mg/Sodium Chloride 0.9% 250 mL CSP, barcode719803357553V28, on 04/10/26.
C. Your firm did not incubate all intact media fill units. A technician completed initial <Redacted B4> gowning competency (glove) qualification, media fill, and post-media fill surface sampling on about 10/30/25. ...
Observation 2
Smoke studies were inadequately performed under dynamic conditions.
Specifically the most recent smoke study video available to review for your <Redacted B4> ISO 5 compounding aseptic <Redacted B4> is dated 07/20/25. It did not contain enough information to verify airflow was suitable for aseptic compounding.
A. There was not enough smoke to visualize airflow in the direct compounding area of the ISO 5 <Redacted B4>. An approximately one-inch diameter stream of smoke was jetted directly onto the critical sites of the simulated CSP and <Redacted B4> from less than one foot away.
B. There was no smoke introduced throughout the ISO 5 <Redacted B4> to determine if there was turbulent flow or dead spots.
C. The two vials and one syringe used to simulate dynamic conditions during the smoke study were not representative of routine operations I observed, or the highest complexity operation used to produce CSPs. ...
Observation 3
Use of non-sterile disinfecting agents in the ISO 5 area.
Specifically,
A.
I watched a compounder wipe the <Redacted B4> bin and all materials needed to produce Category compounded sterile products (CSPs) with nonsterile <Redacted B4> in the unclassified SCA, move these items into the ISO 5 <Redacted B4> and then move the items into the ISO 5 <Redacted B4> <Redacted B4> without wiping them with a sterile disinfectant or sterile <Redacted B4>. Category 1 CSPs produced with these materials include:
• Iron Sucrose 200 mg/Sodium Chloride 0.9% 100 mL CSP, barcode 73513V15, on 04/09/26
B. I watched a compounder disinfect all surfaces in the ISO 5 <Redacted B4> and unclassified segregated compounding area (SCA) with nonsterile <Redacted B4> production and <Redacted B4> during the day per the approved procedure SOP 119-19-12. CSPs produced in the <Redacted B4> include;
• Iron Sucrose 200 mg/Sodium Chloride 0.9% 100 mL CSP, barcode 73513V15, on 04/09/26
• Remicade (infliximab) 750 mg/Sodium Chloride 0.9% 250 mL CSP, barcode 719803357553V28, on 04/10/26
• Briumvi (ublituximab-xiiy) 450 mg/Sodimn Chloride 0.9% 250 mL CSP, barcode 719803356510V10, on 04/10/26
Observation 4
Lack of disinfection of supplies at each transition from areas of lower quality air to areas of higher quality air.
Specifically,
A. The <Redacted B4> bin, drug product vials, unopened syringes and needles, pack of sterile wipes, pack of sterile gloves, and other materials wiped with <Redacted B4> remained in the unclassified SCA about <Redacted B4> before they were placed into the ISO 5 <Redacted B4> to the ISO 5 <Redacted B4> on the <Redacted B4> ISO 5 <Redacted B4>. The compounder did not sanitize the items again before introducing them into the ISO <Redacted B4> to produce one Remicade (infliximab) 750 mg/Sodium Chloride 0.9% 250 mL CSP, barcode 719803357553V28, 011 04710726.
B. The bottom of the <Redacted B4> bin containing items for the Remicade CSP directly contacted items when the compounder placed it on top of the bin containing sanitized material for a Briumvi CSP. The compounder did not sanitize the items again before introducing them into the ISO 5 <Redacted B4> to produce one Briumvi (ublituximab-xiiy) 450 mg/Sodium Chloride 0.9% 250 mL CSP, barcode 7198033S--6510VI0, 011 04110/26.
Observation 5
Failure to appropriately and regularly clean and disinfect or sterilize equipment located in the ISO 5 area.
Specifically, there was visible residue on the walls and direct compounding area in the ISO 5 <Redacted B4> and ISO 5 <Redacted B4> the during production of sterile products. CSPs produced in the <Redacted B4> include:
Iron Sucrose 200 mg/Sodium Chloride 0.9% 100 mL CSP, barcode 73513Vl5, on 04/09/26
Remicade (inflixiniab) 750 mg/Sodium Chloride 0.9% 250 mL CSP, barcode 719803357553V28, 01104/10/26
D
Briumvi (ublituximab-xiiy) 450 mg/Sodimn Chloride 0.9% 250 mL CSP, barcode 719803356510Vl0, 01104/10/26
Observation 6
Inadequate routine environmental monitoring in the ISO 5 area.
Specifically,
A. Environmental monitoring (EM) and Media Fill records from the previous six months document your firm regularly kept media fill, gloved fingertip and thumb (GFT), and surface EM microbiology samples for multiple weeks, and in one instance more than one month, before sending them to the contract laboratory for incubation and testing. Personnel store the samples in a <Redacted B4> incubator that is not monitored or calibrated at that temperature range. There is inadequate justification to delay initiating incubation. The required incubation scheme for GFT and EM samples per SOP 119-19-12 starts with <Redacted B4> incubation before transfer to <Redacted B4>
B. I observed one tray of <Redacted B4> stored in its <Redacted B4> tray exposed to the light in your inpatient pharmacy. The manufacturer Directions for Use instruct users to protect the <Redacted B4> from light. Compounders use these <Redacted B4> for GFT sampling and surface sampling the direct compounding area inside the ISO-5 <Redacted B4> and <Redacted B4> in the <Redacted B4> ISO 5 <Redacted B4>.
Observation 7
No measurement of room pressure differentials was observed during operations to demonstrate proper airflow.
S p ecifically, your firm does not adequately monitor differential pressure in the <Redacted B4> ISO 5 <Redacted B4>. The <Redacted B4> standard configuration has Minihelic gauges for the <Redacted B4> and <Redacted B4> that are not connected to an audible alarm or alarm indicator light on the <Redacted B4> control panel. Additionally, personnel do not document differential pressure readings from either Minihelic gauge at least <Redacted B4> on days of compounding. CSPs I saw produced inside the <Redacted B4>.
O Iron Sucrose 200 mg/Sodium Chloride 0.9% 100 mL CSP, barcode 73513V15, on 04/09/26
O Remicade (infliximab) 750 mg/Sodium Chloride 0.9% 250 mL CSP, barcode 719803357553V28, on 04/10/26
O Briumvi (ublituximab-xiiy) 450 mg/Sodium Chloride 0.9% 250 mL CSP, barcode 719803356510V10, on 04/10/26
Observation 8
Production areas have difficult to clean or contain porous, particle generating, or visibly dirty equipment or surfaces.
Specifically, your unclassified segregated compounding area (SCA) established within the inpatient pharmacy contains surfaces that are not easily disinfected, impervious, free from drainage, or are particle generating. The SCA does not have specific physical boundaries but is defined as a <Redacted B4> buffer zone around the <Redacted B4> ISO 5 <Redacted B4>. The SCA contains a cracked drop ceiling tile which potentially allows the intrusion of air from the plenum, an exposed sprinkler head, an air supply vent, an approximate I-inch hole in the drywall, textured mineral fiber drop ceiling tiles, <Redacted B4> small incubators, and <Redacted B4> oral solid dose counting machines. These surfaces could compromise the ISO 5 environment, particularly when the <Redacted B4> door is opened during cleaning, maintenance, or componding activities. The SCA floor and ceiling are not included in the <Redacted B4> or <Redacted B4> cleaning and disinfection logs.
State board of pharmacy records
State board of pharmacy records for Alabama are not checked: the Board of Pharmacy sends its license roster only by email, after the requester agrees to terms that limit how the data may be used, and its license verification is an interactive search.
This page restates FDA’s lists. A Form 483, letter or board action is not a finding by this site, and a missing record is not a finding either way. A state license is matched only on the same name, city and state. Follow each link for the original document. Report an error or add a company response.
Sources
- FDA: Compounding: Inspections, Recalls, and other Actions
- FDA Registered Outsourcing Facilities (503B)
- FDA Data Dashboard: inspection classifications and published Form 483s
- FDA: FDA Form 483 Frequently Asked Questions
Records last pulled Nov 15, 2026. Every entry links to the original public record.